三生製藥(01530.HK)中期母公司擁有人應佔純利同比增加24.6%至13.58億元
格隆匯8月29日丨三生製藥(01530.HK)公告,截至2025年6月30日止6個月中期業績,收入人民幣43.56億元。母公司擁有人應佔純利同比增加24.6%至人民幣13.58億元。母公司普通股權益持有人應佔每股盈利人民幣0.57元。
三生製藥爲中國領先的生物技術公司。集團作爲中國生物技術行業的先鋒,在研發、生產及營銷生物醫藥產品方面擁有豐富的經驗。集團的核心商業化產品包括多種生物藥物,即特比澳、重組人促紅素("rhEPO")產品益比奧及賽博爾、益賽普和賽普汀,以及小分子藥物蔓迪。特比澳爲當今全球唯一商業化的重組人血小板生成素("rhTPO")產品。根據IQVIA,於2025年上半年,按銷售額計,特比澳在中國內地血小板減少症治療市場的份額爲63.0%。憑藉兩種rhEPO產品,二十多年來,集團一直爲中國內地rhEPO市場龍頭,於2025年上半年共佔41.5%的總市場份額。益賽普爲中國內地市場推出的首個腫瘤壞死因子("TNF")α抑制劑產品。蔓迪在中國內地米諾地爾市場亦佔主導地位。集團亦通過內部研究及開發("研發")及多項外部戰略合作增加產品以擴大治療領域。
於2025年6月30日,集團積極研發的30項重點產品中,27項於中國內地作爲創新藥物開發。其中,18項爲抗體藥物,6項爲其他生物製品及6項爲小分子藥物。集團擁有14項血液╱腫瘤科在研產品;10項在研產品目標爲自身免疫疾病(包括斑塊狀銀屑病、特應性皮炎、痛風性關節炎等)、眼科疾病(視網膜分支靜脈阻塞("BRVO")及其他疾病;3項腎科在研產品;2項皮膚科在研產品及1項代謝科在研產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.